1-3 of 3
Kevin C. Conlon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52 + T-cell malignancies

Clinical Trials & Observations
Milos D. Miljkovic, Sigrid P. Dubois, Jürgen R. Müller, Bonita Bryant, Elaine Ma, Kevin C. Conlon, Thomas A. Waldmann
Journal: Blood Advances
Blood Adv (2023) 7 (3): 384–394.
https://doi.org/10.1182/bloodadvances.2021006440
Published: 2023
Includes: Supplemental data
Journal Articles

Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma

Anusara Daenthanasanmak, Richard N. Bamford, Makoto Yoshioka, Shyh-Ming Yang, Philip Homan, Baktiar Karim, Bonita R. Bryant, Michael N. Petrus, Craig J. Thomas, Patrick L. Green, Milos D. Miljkovic, Kevin C. Conlon, Thomas A. Waldmann
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2346–2360.
https://doi.org/10.1182/bloodadvances.2021005948
Published: 2022
Includes: Supplemental data
Journal Articles

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia

Clinical Trials & Observations
Sarah Cooley, Fiona He, Veronika Bachanova, Gregory M. Vercellotti, Todd E. DeFor, Julie M. Curtsinger, Paul Robertson, Bartosz Grzywacz, Kevin C. Conlon, Thomas A. Waldmann, David H. McKenna, Bruce R. Blazar, Daniel J. Weisdorf, Jeffrey S. Miller
Journal: Blood Advances
Blood Adv (2019) 3 (13): 1970–1980.
https://doi.org/10.1182/bloodadvances.2018028332
Published: 2019
Includes: Supplemental data